Reynolds Bradley R, McCombie Steve, Botha Erica, Hawks Cynthia, Brown Matthew, Hayne Dickon
Department of Urology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
UWA Medical School, The University of Western Australia, Perth, Western Australia, Australia.
ANZ J Surg. 2021 Apr;91(4):565-570. doi: 10.1111/ans.16439. Epub 2020 Nov 24.
Urgent assessment of haematuria is critical to exclude malignancy. The utilization of haematuria clinics in Australia remains in its infancy. It is hoped that the streamlined investigative service will achieve earlier diagnosis of urological malignancy and subsequently decrease morbidity and mortality. We report the 10-year prospectively collected outcomes from Australia's first dedicated one-stop haematuria clinic (OSHC).
Since its commencement in May 2008 through to July 2018, all consecutive patients assessed in the OSHC were included in the analysis. Data collected included demographics, presentation, wait times, investigation, assessment, initial treatment, referral and histopathology.
A total of 3008 patients were seen in the OSHC with non-visible haematuria (1024, 34%) and visible haematuria (1984, 66%). Three hundred and twenty-seven (10.9%) patients were diagnosed with urothelial malignancy. In all, 306 (10.2%) patients had lower tract disease and 21 (0.7%) had upper tract disease. Urothelial cases were compiled of 123 (37.6%) Ta LG, 39 (11.9%) Ta HG, 21 (6.4%) Tis, 67 (20.5%) T1 and 77 (23.6%) T2-4. Urothelial malignancy was diagnosed more often in males (odds ratio (OR) 1.74, 95% confidence interval (CI) 1.35-2.25), older patients elder than 60 years (OR 1.97, 95% CI 1.47-2.64) and patients with visible haematuria (OR 5.42, 95% CI 3.73-7.86). In all, 53.4% of patients were discharged after a single visit to the OSHC.
The OSHC has served as an effective tool for rapid, streamlined assessment of patients presenting with haematuria. This model of care has been subsequently adopted by numerous public centres across Australia. Current funding structures present a barrier to this excellent approach for rapid access diagnostics.
对血尿进行紧急评估对于排除恶性肿瘤至关重要。澳大利亚血尿诊所的利用仍处于起步阶段。人们希望这种简化的检查服务能够更早地诊断出泌尿系统恶性肿瘤,从而降低发病率和死亡率。我们报告了澳大利亚首个专门的一站式血尿诊所(OSHC)10年来前瞻性收集的结果。
自2008年5月开业至2018年7月,所有在OSHC接受评估的连续患者均纳入分析。收集的数据包括人口统计学、临床表现、等待时间、检查、评估、初始治疗、转诊和组织病理学。
OSHC共诊治3008例患者,其中镜下血尿1024例(34%),肉眼血尿1984例(66%)。327例(10.9%)患者被诊断为尿路上皮恶性肿瘤。其中,306例(10.2%)患者患有下尿路疾病,21例(0.7%)患有上尿路疾病。尿路上皮病例包括123例(37.6%)Ta低级别、39例(11.9%)Ta高级别、21例(6.4%)Tis、67例(20.5%)T1和77例(23.6%)T2-4。尿路上皮恶性肿瘤在男性中诊断更为常见(优势比(OR)1.74,95%置信区间(CI)1.35-2.25)、60岁以上的老年患者中(OR 1.97,95%CI 1.47-2.64)以及肉眼血尿患者中(OR 5.42,95%CI 3.73-7.86)。共有53.4%的患者在单次就诊于OSHC后出院。
OSHC已成为对血尿患者进行快速、简化评估的有效工具。这种护理模式随后被澳大利亚众多公共中心采用。目前的资金结构对这种快速获取诊断的优秀方法构成了障碍。